Displaying 71 - 80 of 243
Alternative Name: Casea S
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: GeSea Biosciences, FHI 360
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
User: Male
Hormonal: No
Developer: Eppin Pharma, Inc.
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
Alternative Name: Epididymal Peptidase Inhibitor
Target
User: Male
Hormonal: No
Developer: Eppin Pharma, Inc.
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
Alternative Name: Estetrol (E4) + Drospirenone (DRSP) Combined Pill
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: Mithra
Development Stage: Phase III
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Hera Health Solutions
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Gold T IUD; Novaplus T 380 Ag IUD; Novaplus T 380 Cu IUD; Ancora 375 Ag IUD; Ancora 375 Cu IUD; Ancora 250 Cu Mini IUD
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Eurogine
Development Stage: Marketed
Development Phase: Limited Market Availability
Alternative Name: EVE-106; EVE106; ethinylestradiol prodrugs
User: Female
Hormonal: Yes
Developer: Evestra, Inc.
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Etonogestrel (ENG) + Ethinyl Estradiol (EE) Vaginal Ring; EVE112
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Evestra, Inc., Gedeon Richter Plc.
Development Stage: Phase III
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Evestra, Inc.
Development Stage: Prototype Development
Development Phase: Discovery and Early Development
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Famy Care Ltd.
Development Stage: Marketed
Development Phase: Limited Market Availability

Pages

Displaying 41 - 50 of 70
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Merck
Development Stage: Prototype Development
Alternative Name: Metalloprotease
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University
Development Stage: Target Validation
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Microchips Biotech, Inc.
Development Stage: Prototype Development
Target
User: Male
Hormonal: No
Developer: University of Kansas Medical Center, University of Minnesota
Development Stage: Target Validation
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Washington University
Development Stage: Compound ID/Selection
Alternative Name: Lavax Vaginal Suppository
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other
Developer: Lavax
Development Stage: Lead Optimization
User: Male
Hormonal: No
Delivery Method: Oral
Developer: North Shore University Hospital in New York
Development Stage: Lead Optimization
Alternative Name: Nomegestrol acetate (NOMAC) vaginal ring
User: Female
Hormonal: Yes
Delivery Method: Vaginal Ring
Developer: Merck
Development Stage: Prototype Development
User: Female, Male
Duration Type: Short-acting, Pericoital
Delivery Method: Injectable, Vaginal, Other, Other
Development Stage: Lead Optimization
User: Male
Hormonal: Yes
Developer: University of Kansas Medical Center, University of Minnesota
Development Stage: Lead Optimization

Pages

Displaying 11 - 20 of 121
Alternative Name: Epididymal Calchlorin
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Injectable
Developer: Parsemus Foundation
Development Stage: Pre-clinical
Alternative Name: Capronor Biodegradable Implant
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: RTI International, NICHD
Development Stage: Phase II
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: University of Rajasthan, India
Development Stage: Phase I
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: CEMAG
Development Stage: Pre-clinical
User: Male
Hormonal: No
Duration Type: Permanent, Long-acting
Delivery Method: Vas Deferens
Developer: National Research Institute for Family Planning in Beijing
Development Stage: Phase II
User: Female
Hormonal: Yes
Delivery Method: Transdermal
Developer: Viramal Limited
Development Stage: Pre-clinical
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel, Vaginal, Other
Developer: Central Drug Research Institute, India, HLL Lifecare Limited
Development Stage: Regulatory
Alternative Name: BioRings Intravaginal Ring
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: BioRings, Weill Cornell Medical College, QPharma
Development Stage: Pre-clinical
Alternative Name: Carboxy Terminus Peptide of β-human chorionic gonadotropin
User: Female
Hormonal: No
Developer: WHO, Talwar Research Foundation
Development Stage: Phase II
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral, Subdermal
Developer: University of Edinburgh
Development Stage: Phase II

Pages

Displaying 51 - 52 of 52
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Yantai Family Planning Medicine & Apparatus Co. Ltd., China
Development Stage: Marketed
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Yantai Family Planning Medicine & Apparatus Co. Ltd., China
Development Stage: Marketed

Pages

CSV